Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GutHeart
NCT02637167Phase 2Unknown
- Sponsor
- Oslo University Hospital
- Start
- Mar 2016
- Primary completion
- Jun 2019
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifaximin, saccharomyces boulardii, sponsored by Oslo University Hospital. Status: unknown.
02
Drugs
rifaximinsaccharomyces boulardii
Beyond the preview
Go deeper on NCT02637167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637167.